首页|瑞舒伐他汀联合芪参益气滴丸治疗高血压病合并冠状动脉粥样硬化性心脏病疗效及对动脉斑块的影响

瑞舒伐他汀联合芪参益气滴丸治疗高血压病合并冠状动脉粥样硬化性心脏病疗效及对动脉斑块的影响

扫码查看
目的 探讨瑞舒伐他汀联合芪参益气滴丸治疗高血压病合并冠状动脉粥样硬化性心脏病的疗效及对动脉斑块的影响.方法 选择2021年1月—2021年12月120例高血压病合并冠状动脉粥样硬化性心脏病患者作为研究对象,采用随机数字法平均分为观察组与对照组,两组患者均给予抗血小板聚集及瑞舒伐他汀稳定斑块等治疗措施,观察组在此基础上联合芪参益气滴丸治疗.比较两组患者临床疗效,心功能、血脂水平、颈动脉斑块及不良反应发生情况.结果 观察组总有效率明显高于对照组(P<0.05).随之治疗时间延长,两组患者左心射血分数(left ventricular ejection fractions,LVEF)及左心室收缩末内径(left ventricular end-diastolic dimension,LVEDD)均逐渐改善(P<0.05);治疗后 14 d、3 月观察组LVEF及LVEDD均高于对照组(P<0.05).两组患者治疗后甘油三酯、血清总胆固醇、低密度脂蛋白胆固醇、同型半胱氨酸、C-反应蛋白均逐渐改善(P<0.05);治疗后3个月、6个月观察组甘油三酯、血清总胆固醇、低密度脂蛋白胆固醇、同型半胱氨酸、C-反应蛋白低于对照组(P<0.05).两组患者治疗后颈动脉内中膜厚度(carotid intima-media thickness,IMT)及不稳定斑块比例逐渐降低(P<0.05);治疗后3个月、6个月观察组IMT急不稳定斑块比例低于对照组(P<0.05).两组不良反应发生率比较差异无统计学意义(P>0.05).结论 瑞舒伐他汀联合芪参益气滴丸可以更好地促进高血压病伴颈动脉硬化急性心肌梗死患者恢复,更快使血脂异常达标,更有效地抑制颈动脉不稳定斑块形成,且并未增加不良反应.
Effect of Rosuvastatin Combined with Qishen Yiqi Dripping Pill(芪参益气滴丸)on Hypertension Complicated with Coronary Atherosclerotic Heart Disease and Its Influence on Arterial Plaque
Objective To observe the effect of rosuvastatin combined with Qishen Yiqi Dripping Pill(芪参益气滴丸)on hy-pertension complicated with coronary atherosclerotic heart disease and its influence on arterial plaque.Methods A total of 120 pa-tients with hypertension combined with coronary atherosclerotic heart disease from January 2021 to December 2021 were selected as the research subjects,and they were equally divided into the observation group and the control group by the random number method.The patients in the two groups were given anti-platelet aggregation and rosuvastatin stable plaque treatment.On this basis,the observation group was treated with Qishen Yiqi Dropping Pill.The clinical efficacy,cardiac function,blood lipid levels,carotid plaque and adverse reaction were compared between the two groups.Results The total effective rate in the observation group was significantly higher than that in the control group(P<0.05).With the prolongation of treatment time,the values of left ventricular ejection fractions(LVEF)and left ventricular end-diastolic dimension(LVEDD)of patients in the two groups gradu-ally improved(P<0.05).The values of LVEF and LVEDD in the observation group were higher than those in the control group on day 14 and 3 months after treatment(P<0.05).After treatment,the levels of triglycerides,serum total cholesterol,low density lipoprotein cholesterol,homocysteine and C-reactive protein were gradually improved in both groups(P<0.05).The levels of triglycerides,serum total cholesterol,low density lipoprotein cholesterol,homocysteine and C-reactive protein in the observation group were lower than those in the control group 3 and 6 months after treatment(P<0.05).The values of carotid intima-media thickness(IMT)and the proportion of unstable plaques in the two groups gradually decreased after treatment(P<0.05).The proportion of IMT unstable plaques in the observation group was lower than that in the control group 3 and 6 months after treat-ment(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclu-sion Rosuvastatin combined with Qishen Yiqi Dripping Pill could better promote the recovery of patients with acute myocardial in-farction of hypertension with carotid arteriosclerosis,achieve the standard of dyslipidemia faster and more effectively reduce the formation of carotid unstable plaques without increasing adverse reactions.

rosuvastatinQishen Yiqi Dripping Pill(芪参益气滴丸)hypertensioncoronary atherosclerotic heart diseasearterial plaque

惠慧、王转转、廖梅、李光智、吴光鹏

展开 >

海南省中医院,海南 海口 570000

瑞舒伐他汀 芪参益气滴丸 高血压病 冠状动脉粥样硬化性心脏病 动脉斑块

海南省卫生健康行业科研项目

21A200101

2024

中华中医药学刊
中华中医药学会 ,辽宁中医药大学

中华中医药学刊

CSTPCD北大核心
影响因子:1.007
ISSN:1673-7717
年,卷(期):2024.42(1)
  • 22